A Phase III study to evaluate the combined effects of Avastin and chemotherapy in patients with advanced gastric cancer reported that overall survival was worse in patient groups that strongly expressed tumor NRP1 than in patients with low baseline expression levels (Van Cutsem et al., 2012), suggesting that NRP1 is tumorigenic. The gene discussed is NRP1; the disease is gastric cancer.